Treprostinil

CAS No. 81846-19-7

Treprostinil( LRX-15 | Orenitram | Remodulin )

Catalog No. M19938 CAS No. 81846-19-7

Treprostinil is a potent DP1 IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 55 In Stock
5MG 65 In Stock
10MG 110 In Stock
25MG 234 In Stock
50MG 367 In Stock
100MG 551 In Stock
200MG 780 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Treprostinil
  • Note
    Research use only, not for human use.
  • Brief Description
    Treprostinil is a potent DP1 IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).
  • Description
    Treprostinil is a potent DP1 IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).
  • In Vitro
    Treprostinil has high affinity for the DP1, EP2 and IP receptors (Ki=4.4, 3.6 and 32 nM, respectively), low affinity for EP1 and EP4 receptors and even lower affinity for EP3, FP and TP receptors. Activation of IP, DP1 and EP2 receptors, as with treprostinil, can all result in vasodilatation of human pulmonary arteries.Treprostinil inhibits viability of cultured endothelial colony forming cells. Endothelial colony forming cells proliferation is stimulated by conditioned media from Treprostinil pretreated mesenchymal stem cells.
  • In Vivo
    Inhaled treprostinil sodium, a prostacyclin analog, is the most recent agent to receive FDA approval for the treatment of a fatal orphan disease: pulmonary arterial hypertension (PAH). Treprostinil preserves the sinusoidal endothelial cell lining and reduces platelet deposition early post-transplantation compared to placebo. Hepatic tissue blood flow is significantly compromised in the placebo group, whereas treprostinil maintains blood flow similar to normal levels.Treprostinil treatment significantly increases the vessel-forming ability of endothelial colony forming cells combined with mesenchymal stem cells in Matrigel implanted in nude mice. Silencing VEGF-A gene in mesenchymal stem cells also blocks the pro-angiogenic effect of Treprostinil. Treprostinil is most efficacious in raising intracellular cAMP levels in murine and human hematopoietic stem and progenitor cells. Treatment with Treprostinil significantly reduces the recruitment of cells compared to normoxic mice. Treprostinil also reduces right ventricular systolic pressure and slightly reduces the vascular remodelling but fails to reverse the right ventricular hypertrophy.
  • Synonyms
    LRX-15 | Orenitram | Remodulin
  • Pathway
    GPCR/G Protein
  • Target
    Prostaglandin Receptor
  • Recptor
    DP1 IP EP2
  • Research Area
    Cardiovascular Disease
  • Indication
    Pulmonary hypertension

Chemical Information

  • CAS Number
    81846-19-7
  • Formula Weight
    390.51
  • Molecular Formula
    C23H34O5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 40 mg/mL;Ethanol: 20 mg/mL
  • SMILES
    CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Whittle BJ et al. Binding and activity of the prostacyclin receptor (IP) agonists treprostinil and iloprost at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012 Jul 1;84(1):68-75.
molnova catalog
related products
  • Tafluprost

    Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern.

  • TG6-129

    TG6-129 is an antagonist of the EP2 receptor. TG6-129 suppresses PGE2-induced elevation of cAMP in cells expressing EP2 with an IC50 value of 1.6 μM.

  • BGC201531

    BGC201531 is a EP4 antagonist for the treatment of acute migraine.